Beaird Harris Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Beaird Harris Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$643	Hold	1	–	–	﹤0.01%	588
2026 Q1	$796	Hold	1	–	–	﹤0.01%	546
2025 Q4	$796	Hold	1	–	–	﹤0.01%	573
2025 Q3	$580	Buy	+1	New	+$565	﹤0.01%	603
2025 Q2	–	Sell	-5	Closed	-$3.17K	–	634
2025 Q1	$3.17K	Hold	5	–	–	﹤0.01%	412
2024 Q4	$3.56K	Hold	5	–	–	﹤0.01%	396
2024 Q3	$5.26K	Hold	5	–	–	﹤0.01%	375
2024 Q2	$5.6K	Hold	5	–	–	﹤0.01%	435
2024 Q1	$4.81K	Hold	5	–	–	﹤0.01%	392
2023 Q4	$4.39K	Buy	+5	New	+$4.12K	﹤0.01%	396
2023 Q1	–	Sell	-23	Closed	-$16.6K	–	689
2022 Q4	$16.6K	Buy	+23	New	+$17K	﹤0.01%	278

Other funds holding REGN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

HCM

Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Beaird Harris Wealth Management's REGN Position: Q2 2026 in Review

Beaird Harris Wealth Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 1 share worth $643. The position accounts for ﹤0.01% of the portfolio, ranked #588.

Beaird Harris Wealth Management first reported a position in REGN in Q4 2022 and has held it in 11 quarters since. The position peaked at $16.6K in Q4 2022. 180 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Beaird Harris Wealth Management held 1 share of Regeneron Pharmaceuticals worth $643 as of Q2 2026.
Beaird Harris Wealth Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #588 holding.
Beaird Harris Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Beaird Harris Wealth Management's Regeneron Pharmaceuticals position peaked at $16.6K in Q4 2022.
180 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.